Boehringer Ingelheim reports 11% growth in IMETA in 2025, led by continued momentum and innovation
- IMETA net sales reached EUR 884 million in 2025 from EUR 798 million in 2024
- Globally, group net sales increased 7.3% to EUR 27.8 billion
- Global R&D investments rose to EUR 6.4 billion, representing 22.9% of group net sales, across its markets
- 70 million patients reached globally in 2025
Boehringer Ingelheim, one of the world’s leading biopharmaceutical companies, reported strong growth across India, Middle East, Turkey and Africa (IMETA) region in 2025, with net sales reaching EUR 884 million, compared to EUR 798 million in 2024, marking an 11% increase year on year. The performance reflects continued demand across key therapeutic areas and the company’s long-term commitment to expanding access to innovative care across diverse healthcare systems in the region.
Globally, 2025 marked an important year for the company’s innovation journey, including the launch of two new medicines with FDA Breakthrough Therapy designation for non-small lung cancer and pulmonary fibrosis, reinforcing its focus on addressing areas of high unmet medical need.
Commenting on the growth, Derek O’Leary, Regional Managing Director, Boehringer Ingelheim IMETA, said: “IMETA is one of the most diverse regions we operate in, spanning markets at very different stages of healthcare maturity, regulatory environments and cultural contexts. What unites them, however, is a clear shift towards strengthening health systems and investing in long-term outcomes.
Our growth in the region is a result of staying close to these realities, building the right partnerships, expanding access in a responsible way, and aligning our efforts to national priorities across both human and animal health.”
“At the same time, we are able to bring the strength of our global innovation pipeline into the region in a way that is locally relevant. This combination of global science and local understanding is what continues to drive momentum for us. Looking ahead, IMETA is a growth region that is increasingly shaping how healthcare evolves.
We see a real opportunity for the region to set new benchmarks for integrated, future-ready health systems, and we are committed to playing a long-term role in that journey,” added O’Leary.
Globally, Boehringer recorded net sales of EUR 27.8 billion in 2025, supported by both the Human Pharma and Animal Health business, representing a 7.3% increase compared to the previous year. The company continued to invest significantly in innovation, with Research and Development (R&D) investment reaching EUR 6.4 billion, representing 22.9% of group net sales. Overall, the company reached 70 million patients globally in 2025, delivering innovative medicines to more patients than ever before.
Frank Hübler, Member of the Board of Managing Directors responsible for Finance, said: “In volatile markets and amid regional challenges, our business proved resilient as we focused on what we do best: bringing more medicines to patients and animals. We are investing more than ever in innovation, which reflects our ambition for the next years.”
Worldwide and in Human Pharma, Boehringer Ingelheim continued to build on its core portfolio while advancing its pipeline across cardiovascular, renal and metabolic diseases, oncology, respiratory and immunology, mental health, and eye health. The pipeline today includes more than 80 projects, representing over 50 new molecular entities.
Ongoing advances in Boehringer’s growing mid‑ and late‑stage pipeline are building towards a sustained wave of potential launches, positioning the company to deliver transformative impact for patients in the years to come. Human Pharma sales increased 7.4% to EUR 22.7 billion in 2025, with R&D investments reaching EUR 5.8 billion, or 27.4% of net sales.
Shashank Deshpande, Chairman of the Board of Managing Directors and responsible for Human Pharma, said: “2025 reinforced the strength of our pipeline and underscored the impact of our long-term investment in R&D. With two newly launched medicines in oncology and respiratory, we are addressing high unmet medical needs of patients, while also driving the renewal of our portfolio.
Our pipeline positions us well to continue to make a real difference across important disease areas, and to bring innovative therapies to more patients than ever. As 2026 unfolds with pivotal Phase III programs and readouts as well as new launches ahead, we strive to improve the lives of patients, animals, and communities worldwide.”
The Animal Health business also delivered steady growth globally, with sales rising 6.5% to EUR 4.9 billion, demonstrating resilience and impact. Growth was driven by pet parasiticides and therapeutics, poultry, and ruminant segments, cementing its position as the industry’s top-selling parasiticide brand. The company worked side by side with farmers, veterinarians, and governments, to help combat livestock diseases such as avian influenza, foot-and-mouth disease, and bluetongue virus.
As the company moves into 2026, Boehringer Ingelheim will continue to build on this momentum through sustained investment in innovation and a strong focus on areas of high unmet need across both human and animal health.
